Eisai has filed for approval in Japan for tasurgratinib, its small-molecule fibroblast growth factor (FGF) receptor inhibitor, as a treatment for biliary tract cancers with FGFR2 gene fusion ...

Expression of Trop2, Nectin-4, and FOLR1 cell surface markers in biliary tract cancers: Is it time to repurpose drugs? This is an ASCO Meeting Abstract from the 2025 ASCO Gastrointestinal Cancers ...

It was approved by the MHLW on the strength of a single-arm phase 2 trial (Study 201) that enrolled patients in Japan and China with FGFR2 gene fusion-positive unresectable BTC that had previously ...